Biomarkers and Choroidal Neovascularization
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorInstitut National de la Santé Et de la Recherche Médicale, France
About this trial
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.
Eligibility criteria
Qualifiers
Patients with type 1 choroidal neovascularization in a context of central serous chorioretinoathy or age related macular degeneration
Patients without intravitreal injection or last intravitreal injection > 3 months
Informed signed consent
Patients without choroidal neovascularization
Disqualifiers
Myocardial infarction < 12 months
Chronic renal failure
Inflammatory disease
Infectious disease :HIV, viral hepatitis, tuberculosis
Trial design
Treatments tested in this trial
- Blood and aqueous humor biomarker of treatment response
Treatment groups
250 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov